Compare LCNB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | NERV |
|---|---|---|
| Founded | 1877 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 210.1M |
| IPO Year | 1999 | 2014 |
| Metric | LCNB | NERV |
|---|---|---|
| Price | $19.92 | $4.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 40.0K | ★ 157.7K |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $6,445,000.00 | ★ $41,175,600.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $63.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.21 | $1.76 |
| 52 Week High | $21.32 | $12.46 |
| Indicator | LCNB | NERV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.